ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1543	National Cancer Institute	Html	en	Adult Acute Lymphoblastic Leukemia Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of adult acute lymphoblastic leukemia.	red blood cells 0.657008 treatment 0.69838 cancer treatment 0.510853 stored stem cells 0.432024 myeloid stem cell 0.410543 abnormal cells 0.408626 cord). 0.586593 immature blood cells 0.444877 blast cells 0.409519 CNS prophylaxis 0.43336 cancer cells 0.637541 lymphoid stem cell 0.411207 type 0.407802 chemotherapy 0.418061 PDQ cancer information 0.486683 specific cancer cells 0.45646 clinical trial search 0.434142 white blood cells 0.722058 stem cell 0.530795 treatment clinical trials 0.437953 blood stem cells 0.480973 National Cancer Institute 0.448039 clinical trials 0.958798 mature blood cells 0.496196	Natural killer cells 0.443636 normal cells 0.428739 cancer information summary 0.448111 clinical trial 0.624583 new treatment 0.467045 stem cell transplant 0.495713 kinase inhibitor therapy 0.4731 Lymphoblastic Leukemia Treatment 0.414582 chance leukemia cells 0.460746 patients 0.42006 blood cells 0.731186 bone marrow 0.727339 immature cells 0.419809 CAR T-cell therapy 0.438682 cells 0.839029 cancer clinical trials 0.459465 acute lymphoblastic leukemia 0.946164 radiation therapy 0.527726 Treatment Editorial Board 0.410648 cancer 0.8076 standard treatment 0.454915 tyrosine kinase inhibitor 0.516075 leukemia cells 0.619353	CLICK HERE
1598	National Cancer Institute	Html	en	Nutrition in Cancer Care (PDQ®)–Health Professional Version	Expert-reviewed information summary about the causes and management of nutrition problems that occur in patients with cancer.	Oncology Nutrition Dietetic 0.634094 obese cancer patients 0.674849 World Cancer Research 0.619802 Cancer Research Fund 0.619994 artificial nutrition 0.652387 Community Cancer Centers 0.700876 Cancer Program Guidelines 0.624097 nutrition status 0.695452 nutrition screening 0.627502 Nutrition Therapy section 0.64247 cancer cachexia therapy 0.631345 enteral nutrition 0.709727 patients 0.881369 cancer patients 0.790895 weight loss 0.81132 oral nutrition supplements 0.689897 immunocompromised cancer patients 0.638801 North Central Cancer 0.622864 megestrol acetate 0.683197 Parenter Enteral Nutr 0.674425 nutrition 0.853145 cancer survivors 0.617965 radiation therapy 0.659649 Nutr Clin Pract 0.657573 Nutrition Dietetic Practice 0.630177	et al. 0.712864 treatment 0.690326 lean body mass 0.682169 parenteral nutrition support 0.641552 terminal cancer patients 0.643213 PUBMED Abstract 0.761858 parenteral nutrition 0.727185 Support Care Cancer 0.683396 experimental cancer cachexia 0.632271 oncology nutrition care 0.62028 nutrition care plan. 0.617909 health care 0.624711 Cancer Treatment Group 0.649077 advanced cancer 0.631851 Clin Nutr 0.671517 cancer patients. 0.625985 cancer cachexia 0.838737 Clin Oncol 0.670786 nutrition support therapy 0.618651 systematic review 0.80665 Central Cancer Treatment 0.648181 Cancer J Clin 0.618652 Cancer cachexia syndrome 0.625914 cancer 0.942013	CLICK HERE
1615	National Cancer Institute	Html	en	Cardiopulmonary Syndromes (PDQ®)–Health Professional Version	Expert-reviewed information summary about common conditions that produce chest symptoms. The cardiopulmonary syndromes addressed in this summary are cancer-related dyspnea, malignant pleural effusion, pericardial effusion, and superior vena cava syndrome.	vena cava 0.611223 pericardial tamponade 0.679952 evidence 0.62034 randomized controlled trials 0.605832 malignant pleural effusion 0.70666 pericardial fluid collection 0.700496 significant pericardial effusions 0.706328 underlying malignant disorders 0.602719 right mainstem bronchus 0.652149 chest 0.626465 cancer patients 0.972375 malignant pericardial effusion. 0.719099 Cancer Dyspnea Scale 0.624114 subxiphoid pericardial windows 0.680282 treatment 0.619895 nonmalignant causes 0.594571 Pericardial biopsy 0.658961 pericardial effusions. 0.666377 pericardial sac. 0.661251 dyspneic cancer patients 0.638184 pericardial sclerosis 0.657248 Pericardial friction rubs 0.684646 subxiphoid pericardial window 0.711885 loculated pleural effusions 0.605868 pericardial effusion 0.810932	pericardial sac 0.692904 advanced lung cancer 0.597362 terminally ill patients 0.609314 large pleural effusion 0.611685 pulmonary function tests 0.594337 Pericardial fluid cytology 0.702526 inoperable cancer patients 0.631248 lung cancer patients 0.649316 Recurrent pericardial effusion 0.706493 dyspnea 0.731471 pericardial masses 0.661922 pericardial fluid reaccumulation 0.694759 pericardial mesothelioma 0.66558 respiratory muscle dysfunction 0.634779 inferior vena cava 0.596175 nebulized local anesthetics 0.604885 pericardial sclerotherapy 0.657003 chest pain 0.622877 malignant pericardial effusions 0.808201 pericardial sclerosis. 0.657675 malignant pleural effusions 0.666328 pericardial effusions 0.86832 chest x-ray 0.605659 pericardial drainage 0.663513	CLICK HERE
1620	National Cancer Institute	Html	en	Myelodysplastic/ Myeloproliferative Neoplasms Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of myelodysplastic/myeloproliferative neoplasms including chronic/juvenile myelomonocytic leukemias and atypical CML.	red blood cells 0.768748 cancer treatment 0.388453 blood -forming cells 0.422515 blast cells 0.38801 PDQ cancer information 0.4465 clinical trial search 0.417483 white blood cells 0.789303 myelodysplastic /myeloproliferative neoplasm 0.381874 abnormal blood cells 0.425458 clinical trials 0.736543 mature blood cells 0.494148 myelomonocytic leukemia 0.471388 chronic myelomonocytic leukemia 0.433936 cancer information summary 0.411963 clinical trial 0.54455 patients 0.384599 blood cells 0.912354 chronic myelogenous leukemia 0.426541 immature cells 0.400391 platelets 0.382322 NCI PDQ cancer 0.377587 supportive care 0.382497 Treatment Editorial Board 0.386238 treatment 0.557882	stored stem cells 0.41047 myeloid stem cell 0.393162 immature blood cells 0.507153 blood stem cell 0.390434 cancer cells 0.421289 lymphoid stem cell 0.393903 Easy bruising 0.397179 atypical CML 0.383221 treatment clinical trials 0.403674 blood stem cells 0.764143 National Cancer Institute 0.413265 normal cells 0.378893 juvenile myelomonocytic leukemia 0.471101 new treatment 0.442289 white blood cell 0.40841 healthy red blood 0.434016 bone marrow 0.568618 myelodysplastic/ myeloproliferative neoplasms 0.38491 cells slowly increases 0.413624 cancer clinical trials 0.423855 myelodysplastic/myeloproliferative neoplasm 0.393131 immature white blood 0.444308 treatment options 0.378048 leukemia cells 0.390336	CLICK HERE
1851	National Cancer Institute	Html	es	Tratamiento del cáncer de tiroides (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del cáncer de tiroides.	siguientes procedimientos 0.422153 hormona tiroidea 0.492622 bLos ganglios 0.448367 Hürthle cell carcinoma 0.418971 mínima diseminación 0.464789 T4b Enfermedad 0.438377 American Cancer Society 0.43686 European Thyroid Association 0.427771 thyroid disease 0.486942 niveles i 0.45199 Thyroid Association 0.441602 fase iii 0.434728 Natl Cancer Inst 0.440945 Thyroid calcification 0.433055 thyroid with 0.432277 Prognostic factors 0.431082 ≤2 cm 0.731745 patients with 0.416562 tiroides estadio 0.461688 N1a Metástasis 0.590742 N1b Metástasis 0.55338 American Thyroid Association 0.427447 papillary thyroid carcinoma 0.534329 tejidos blandos peritiroideos 0.507165 glándula tiroides 0.891491	tumores papilares 0.421501 nivel vii 0.450974 Lennard CM 0.428158 tiroides tipo 0.453807 ablación tiroidea 0.436707 French Thyroid Cancer 0.436044 M0 T1 0.439686 thyroid cancer 0.993324 cápsula tiroidea 0.541937 thyroid carcinoma with 0.448553 tejidos blandos subcutáneos 0.474653 differentiated carcinoma 0.433423 follicular thyroid carcinomas 0.439446 thyroid carcinoma depends 0.445887 thyroid carcinomas 0.753573 Surg Oncol 0.439117 pronóstico adverso 0.424396 cartílagos tiroides 0.469208 Thyroid tumors 0.433 estadios tnm 0.421127 American Joint Committee 0.423622 ganglios linfáticos retrofaríngeos 0.70543 lobectomía tiroidea 0.423995 AJCC Cancer Staging 0.417512	CLICK HERE
1926	National Cancer Institute	Html	es	Tratamiento de la leucemia de células pilosas (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento de la leucemia de células pilosas.	células madre 0.33069 leucemia linfoblástica aguda 0.322509 siguientes afecciones 0.302348 hueso compacto 0.308819 neoplasias mieloides 0.302225 vía oral 0.301703 rayos x 0.301869 gen braf 0.305773 largo plazo 0.304831 célula madre mieloide 0.311776 National Cancer Institute 0.301791 siguientes riesgos 0.301225 células pilosas 0.98731 Instituto Nacional 0.306123 PDQ Tratamiento 0.305303	célula madre linfoide 0.305127 Linfocitos T 0.303214 siguientes problemas 0.302353 leucemia mielógena 0.31078 Drugs Approved 0.301713 Physician Data Query 0.306482 anticuerpo monoclonal rituximab 0.304903 anticuerpo monoclonal usa 0.304464 Hairy Cell Leukemia 0.302945 leucemia mieloide aguda 0.322517 siguientes enlaces 0.301398 célula madre 0.330149 células sanguíneas maduras 0.327581 ósea elabora células 0.315738	CLICK HERE
3517	National Cancer Institute	Html	en	Randomization and Bias in Cancer Clinical Trials	Information about randomization and bias in cancer clinical trials.	different treatments 0.635974 Single-blinded trials 0.587003 treatment 0.879587 instance 0.449169 simplest trial design 0.829657 human choices 0.621077 control group 0.779296 trial 0.855759 example 0.496876 points 0.446685 different health changes 0.763108 randomization 0.811688 bias 0.660255 Double-blinded trials 0.584527 clinical trials 0.60736 end 0.493376 group 0.945379 clinical trial 0.755171	phase 0.504191 new treatment 0.781754 process 0.451025 chance 0.58412 researchers 0.446538 patients 0.774398 trial results 0.587968 treatment trials 0.574174 groups 0.737104 investigational group 0.633981 people 0.445658 way 0.48098 healthier patients 0.602713 treatment group 0.70095 doctors 0.497874 unusual side effects 0.592351 sicker patients 0.596186 standard therapy 0.638086	CLICK HERE
15777	National Cancer Institute	Html	en	Research Directions for Childhood Cancer	NCI has identified areas for which more research is needed on childhood cancers, including investments in basic research, immunotherapies, and moleculary targeted therapies.	small molecule inhibitors 0.412891 childhood cancers 0.94672 critical gaps 0.332101 major treatment advance 0.412137 Pediatric MATCH 0.392576 research proposals 0.436951 peer review process 0.389826 immunotherapy technique 0.352473 NCI scientists Lawrence 0.622389 chimeric antigen receptor 0.460833 cancer cells 0.401044 highly trained scientists 0.390662 high-priority goal 0.343491 cancer research 0.527941 best scientific proposals 0.421088 pediatric patients 0.416725 pediatric cancer 0.412777 research areas 0.34678 T-cell receptor 0.362608 specific disease area 0.405285 clinical trials 0.669991 immunotherapy treatments 0.349585 NCI leadership 0.495193 Tumor DNA sequencing 0.405564	Pediatric Brain Tumor 0.687267 NCI-COG Pediatric Molecular 0.487101 NCI-sponsored clinical trials 0.416329 cancer immunology 0.348212 research funding decisions 0.424865 NCI funding opportunities 0.589573 rigorous grant application 0.388949 NCI portfolio 0.493947 rapidly advancing field 0.423802 new approaches 0.32698 advanced cancers 0.402816 research topic 0.333717 Pediatric Oncology Branch 0.692641 young adult patients 0.616776 NCI 0.771754 Children’s Oncology 0.432835 research category 0.33728 Brain Tumor Consortium 0.615122 Oncology Group 0.433591 NCI’s Steven 0.52013 past decade 0.330224 NCI Center 0.621549 adoptive cell transfer 0.42055	CLICK HERE
16145	National Cancer Institute	Html	es	Virus de la enfermedad de Newcastle (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos sobre el uso del virus de la enfermedad de Newcastle (VEN) como tratamiento para las personas con cáncer.	células anfitrionas 0.602816 Centro Nacional 0.427496 inmunitario fabrique anticuerpos 0.432469 New Hampshire Avenue 0.419687 PDQ Virus 0.451192 complicaciones quizás 0.416168 Drug Administration 0.41221 NCI Best Case 0.435079 datos bibliográficos pubmed 0.420843 posibles formas 0.415768 largo plazo 0.415867 mayoría usó células 0.468567 fase ii 0.489698 único efecto 0.414956 National Cancer Institute 0.423353 siguientes riesgos 0.413615 cepa mth-68 0.496578 distintos factores 0.416278 Instituto Nacional 0.505259	acupuntura ayuda 0.4111 células tumorales enteras 0.475674 Salud Complementaria 0.443057 sustancias llamadas citocinas 0.426511 Visuals Online 0.413937 complementarias revisa 0.419519 Physician Data Query 0.480164 cuarto estudio 0.414722 Estados Unidos 0.771775 células enteras 0.494193 libre uso 0.416835 página manejo 0.41298 ¿El tratamiento 0.429077 ¿Los beneficios 0.412098 juntos cam 0.411689 suficientes resultados prometedores 0.425777 células renales 0.45757 Series Program 0.411543 medicina complementaria 0.961806	CLICK HERE
16811	National Cancer Institute	Html	es	Cartílago (bovino y de tiburón) (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos sobre el uso de cartílago bovino y de tiburón como tratamiento para personas con cáncer. Nota: la información contenida en este sumario ya no se actualiza y se ofrece solo con fines de consulta.	Shirai E 0.323137 cancer treatment 0.318107 relation with cartilage-derived 0.318214 Langer R 0.391189 Enomoto M 0.357345 Prudden JF 0.438802 Biol Chem 0.333806 shark cartilage 0.967013 shark cartilage with 0.323621 Biol Response Mod 0.535917 Cartilage-derived growth factor 0.322107 tumor angiogenesis 0.329827 cultured endothelial cells 0.316222 Cancer Res 0.3293 inhibitor from shark 0.3338 Natl Cancer Inst 0.381802 novel shark cartilage 0.322776 shark cartilage extract 0.362678 with cartilage-derived anti-tumor 0.3188 powdered shark cartilage 0.321655 Japanese shark cartilage 0.32145 with cartilage-derived 0.324288 Biophys Res Commun 0.316215 Biochem Biophys Res 0.31677 inhibits tumor neovascularization 0.319919	Biol Int Rep 0.323384 stem cell 0.318383 potent shark cartilage-derived 0.318104 Takigawa M 0.353102 tumor growth 0.323007 cartilage extract 0.364849 anti-angiogenic antitumor factor 0.318413 stem cell assay 0.317911 Cell Biol Int 0.327732 its relation with 0.316418 cell line produces 0.317193 Exp Med Biol 0.323654 from cartilage 0.324423 shark cartilage-derived angiogenesis 0.320509 New York 0.316148 antitumor factor 0.334004 endothelial cell 0.365475 Cell Biol 0.339136 cartílago bovino 0.480214 cartilage contains inhibitors 0.320628 angiogenesis inhibitor from 0.364307 from shark cartilage 0.349703 Sudhalter J 0.330756 from japanese shark 0.31927	CLICK HERE